<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489813</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00050273</org_study_id>
    <secondary_id>EU2010-11</secondary_id>
    <nct_id>NCT01489813</nct_id>
  </id_info>
  <brief_title>Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment</brief_title>
  <official_title>Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with non-invasive bladder cancer are often treated with intravesical therapy in&#xD;
      order to prevent the recurrence of bladder cancer. Intravesical therapy can cause many lower&#xD;
      urinary tract symptoms, which can limit the dose of therapy and therefore efficacy of&#xD;
      treatment. There have been a number of studies that suggest a chemical found in soy beans may&#xD;
      be able to help with these side effects. This chemical is called genistein and can be&#xD;
      extracted and given to study subjects in pill form. In this study, the investigators would&#xD;
      like to have patients placed into two different groups. One group would take genistein and&#xD;
      the other group would take a placebo, a sugar pill that looks like the genistein pill. In&#xD;
      doing this study the investigators hope to explore the findings from other studies to see if&#xD;
      lower urinary tract symptoms are reduced and to see if recurrence rates for patients are&#xD;
      affected by genistein. The study would take about four and a half months total.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are treated with bacillus Calmette-Guerin (BCG) intravesical therapy for&#xD;
      non-muscle invasive (TaT1) Tis superficial bladder cancer often develop adverse effects&#xD;
      (urinary tract symptoms) which limit the dose (and therefore the efficacy) of therapy and&#xD;
      result in poor quality of life. Genistein is a nutritional supplement with anti-inflammatory&#xD;
      properties which might help alleviate adverse effects of intravesical therapy that are due to&#xD;
      inflammation. Additionally, genistein also has anti-tumor and immunopotentiating properties&#xD;
      and has been shown to have no known side effects. Our hypothesis is that genistein given&#xD;
      together with BCG intravesical therapy will reduce its adverse effects and improve the&#xD;
      efficacy of therapy. Patients (N=88) scheduled for intravesical therapy will be randomly&#xD;
      assigned to take 30 mg tablets PO TID of genistein supplement (N=44) or placebo (N=44) during&#xD;
      therapy and one month post therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2017</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in severity of urinary symptoms as determined by the IPSS questionnaire score.</measure>
    <time_frame>At 6 weeks of treatment</time_frame>
    <description>The change in severity of urinary symptoms as determined by the International Prostate Symptom Score (IPSS) questionnaire score. IPSS scores at 6 weeks of treatment will be compared to scores at baseline of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of cancer recurrence determined at 10-week biopsy.</measure>
    <time_frame>At 10 weeks of treatment.</time_frame>
    <description>A secondary study endpoint will be the presence of cancer and the rate of recurrence as determined by the 10-week biopsy or subsequent standard follow-up visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be given placebo pills for 10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genistein supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg of genistein supplement by mouth three times daily (PO TID) for 10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genistein</intervention_name>
    <description>30 mg of genistein supplement by mouth three times daily (PO TID).</description>
    <arm_group_label>Genistein supplement</arm_group_label>
    <other_name>Bonistein</other_name>
    <other_name>I-CoolÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>Sugar pills will be taken by mouth three times daily (PO TID).</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Placebo pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female gender&#xD;
&#xD;
          2. 18 years or older&#xD;
&#xD;
          3. Diagnosis of superficial bladder cancer&#xD;
&#xD;
          4. Scheduled for induction BCG intravesical therapy&#xD;
&#xD;
          5. Willing and able to give blood sample&#xD;
&#xD;
          6. Willing and able to fill out a pill diary to ensure compliance&#xD;
&#xD;
          7. Willing and able to sign informed consent&#xD;
&#xD;
          8. Birth control is not required for this study!&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are pregnant&#xD;
&#xD;
          2. Diagnosis of muscle-invasive bladder cancer&#xD;
&#xD;
          3. Unwillingness to follow study protocol and compliance procedures&#xD;
&#xD;
          4. HIV positive or immunocompromised&#xD;
&#xD;
          5. Receiving concurrent immunotherapy or chemotherapy&#xD;
&#xD;
          6. Presence of concurrent second cancer (active, not history)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer Kucuk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Omer Kucuk, MD</last_name>
    <phone>404-778-0897</phone>
    <email>omer.kucuk@emory.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mersiha Torlak, MPH</last_name>
    <phone>404-778-4823</phone>
    <email>mersiha.torlak@emory.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katya Bobrek, BS</last_name>
      <phone>404-778-0897</phone>
      <email>katya.bobrek@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mersiha Torlak, MPH</last_name>
      <phone>404-778-4823</phone>
      <email>mersiha.torlak@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Emory University Department of Urology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katya Bobrek, BS</last_name>
      <phone>404-778-0897</phone>
      <email>katya.bobrek@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mersiha Torlak, MPH</last_name>
      <phone>404-778-4823</phone>
      <email>mersiha.torlak@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katya Bobrek, BS</last_name>
      <phone>404-778-0897</phone>
      <email>katya.bobrek@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mersiha Torlak, MPH</last_name>
      <phone>404-778-4823</phone>
      <email>mersiha.torlak@emory.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Omer Kucuk</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

